IE
FULC icon

Israel Englander’s Fulcrum Therapeutics FULC Stock Holding History

Israel Englander’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.44M Buy
1,485,803
+1,129,332
+317% +$6.87M ﹤0.01% 2921
2026
Q1 		$2.73M Buy
356,471
+302,040
+555% +$2.8M ﹤0.01% 3562
2025
Q4 		$616K Sell
54,431
-96,436
-64% -$981K ﹤0.01% 4815
2025
Q3 		$1.39M Buy
150,867
+45,174
+43% +$327K ﹤0.01% 4357
2025
Q2 		$727K Buy
105,693
+65,001
+160% +$348K ﹤0.01% 4648
2025
Q1 		$117K Sell
40,692
-35,431
-47% -$130K ﹤0.01% 5411
2024
Q4 		$358K Buy
76,123
+52,628
+224% +$194K ﹤0.01% 4972
2024
Q3 		$83.9K Sell
23,495
-379,254
-94% -$2.81M ﹤0.01% 5613
2024
Q2 		$2.5M Sell
402,749
-494,712
-55% -$3.75M ﹤0.01% 3348
2024
Q1 		$8.47M Buy
897,461
+459,958
+105% +$4.11M ﹤0.01% 2348
2023
Q4 		$2.95M Sell
437,503
-567,179
-56% -$2.52M ﹤0.01% 3263
2023
Q3 		$4.46M Buy
1,004,682
+429,825
+75% +$1.88M ﹤0.01% 2804
2023
Q2 		$1.9M Sell
574,857
-45,702
-7% -$134K ﹤0.01% 3525
2023
Q1 		$1.77M Buy
+620,559
New +$5.56M ﹤0.01% 3556
2022
Q3 		– Sell
-81,197
Closed -$398K – 7203
2022
Q2 		$398K Buy
+81,197
New +$793K ﹤0.01% 5134
2022
Q1 		– Sell
-58,375
Closed -$826K – 7085
2021
Q4 		$1.03M Sell
58,375
-41,332
-41% -$819K ﹤0.01% 4376
2021
Q3 		$2.81M Sell
99,707
-525,928
-84% -$9.97M ﹤0.01% 3511
2021
Q2 		$6.56M Buy
625,635
+30,574
+5% +$309K ﹤0.01% 2402
2021
Q1 		$7.01M Buy
595,061
+556,199
+1,431% +$6.88M 0.01% 2189
2020
Q4 		$455K Buy
+38,862
New +$439K ﹤0.01% 4261
2020
Q3 		– Sell
-46,947
Closed -$859K – 4577
2020
Q2 		$859K Sell
46,947
-138,072
-75% -$2.17M ﹤0.01% 3074
2020
Q1 		$2.21M Buy
185,019
+94,838
+105% +$1.52M 0.01% 1946
2019
Q4 		$1.5M Sell
90,181
-220,889
-71% -$2.11M ﹤0.01% 2779
2019
Q3 		$2.06M Buy
+311,070
New +$3.44M ﹤0.01% 2422

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Israel Englander's FULC Position: Q2 2026 in Review

Israel Englander increased its Fulcrum Therapeutics (FULC) stake by 317% in Q2 2026, buying an estimated $6.87M and bringing the position to 1,485,803 shares worth $5.44M. The position accounts for ﹤0.01% of the portfolio, ranked #2921.

Israel Englander first reported a position in FULC in Q3 2019 and has held it in 24 quarters since. The position peaked at $8.47M in Q1 2024. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Israel Englander held 1,485,803 shares of Fulcrum Therapeutics worth $5.44M as of Q2 2026.
  • Israel Englander bought 1,129,332 Fulcrum Therapeutics shares in Q2 2026, an estimated $6.87M.
  • Fulcrum Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2921 holding.
  • Israel Englander first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 24 quarters since.
  • Israel Englander's Fulcrum Therapeutics position peaked at $8.47M in Q1 2024.
  • 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.